肺气肿性胰腺炎死亡的危险因素。

IF 2.4 Journal of Drug Assessment Pub Date : 2019-10-23 eCollection Date: 2020-01-01 DOI:10.1080/21556660.2019.1684927
Chin-Yao Chou, Yu-Jang Su, Hsiu-Wu Yang, Chen-Wang Chang
{"title":"肺气肿性胰腺炎死亡的危险因素。","authors":"Chin-Yao Chou,&nbsp;Yu-Jang Su,&nbsp;Hsiu-Wu Yang,&nbsp;Chen-Wang Chang","doi":"10.1080/21556660.2019.1684927","DOIUrl":null,"url":null,"abstract":"<p><p><b>Objective:</b> To investigate the difference in the characteristics between patients with emphysematous pancreatitis (EP) who survived and those who died. <b>Methods:</b> PubMed search was performed to gather EP cases from March 1959 to February 2019. Forty-two articles with 58 EP cases were identified and met the study's inclusion criteria. The elderly were defined as individuals aged >65 years. Data on patients' demographics, clinical symptoms, laboratory results, treatments, outcomes, and mortality were collected and analyzed by chi-square test and Student's <i>t</i>-test. <i>p</i>-Value <.05 (2-tailed) was set as the significance level. <b>Results:</b> Forty-seven men and eleven women aged 61.3 ± 15.9 (mean ± standard deviation) years were included. The elderly accounted for 43.1% (<i>n</i> = 25) of cases. There were 20 mortality cases, and 38 cases survived, with an overall mortality rate of 34.5%. Sex, underlying diseases, etiologies, and laboratory results were not significantly related to mortality. Older age was significantly related to mortality (<i>p</i> = .001). The shock was more commonly seen in the mortality group (100%) than in the survival group (21%) (<i>p</i> < .001). In contrast, fever was less frequent in the mortality group than in the survival group (25 vs. 71%, <i>p</i> = .002). <b>Conclusions:</b> EP patients have a high mortality rate (34.5%). Older age, afebrile status, and presence of shock are associated with high mortality. To improve the survival of this aggressive group, a further prospective investigation involving a larger sample size is necessary.</p>","PeriodicalId":15631,"journal":{"name":"Journal of Drug Assessment","volume":"9 1","pages":"1-7"},"PeriodicalIF":2.4000,"publicationDate":"2019-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/21556660.2019.1684927","citationCount":"5","resultStr":"{\"title\":\"Risk factors for mortality in emphysematous pancreatitis.\",\"authors\":\"Chin-Yao Chou,&nbsp;Yu-Jang Su,&nbsp;Hsiu-Wu Yang,&nbsp;Chen-Wang Chang\",\"doi\":\"10.1080/21556660.2019.1684927\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Objective:</b> To investigate the difference in the characteristics between patients with emphysematous pancreatitis (EP) who survived and those who died. <b>Methods:</b> PubMed search was performed to gather EP cases from March 1959 to February 2019. Forty-two articles with 58 EP cases were identified and met the study's inclusion criteria. The elderly were defined as individuals aged >65 years. Data on patients' demographics, clinical symptoms, laboratory results, treatments, outcomes, and mortality were collected and analyzed by chi-square test and Student's <i>t</i>-test. <i>p</i>-Value <.05 (2-tailed) was set as the significance level. <b>Results:</b> Forty-seven men and eleven women aged 61.3 ± 15.9 (mean ± standard deviation) years were included. The elderly accounted for 43.1% (<i>n</i> = 25) of cases. There were 20 mortality cases, and 38 cases survived, with an overall mortality rate of 34.5%. Sex, underlying diseases, etiologies, and laboratory results were not significantly related to mortality. Older age was significantly related to mortality (<i>p</i> = .001). The shock was more commonly seen in the mortality group (100%) than in the survival group (21%) (<i>p</i> < .001). In contrast, fever was less frequent in the mortality group than in the survival group (25 vs. 71%, <i>p</i> = .002). <b>Conclusions:</b> EP patients have a high mortality rate (34.5%). Older age, afebrile status, and presence of shock are associated with high mortality. To improve the survival of this aggressive group, a further prospective investigation involving a larger sample size is necessary.</p>\",\"PeriodicalId\":15631,\"journal\":{\"name\":\"Journal of Drug Assessment\",\"volume\":\"9 1\",\"pages\":\"1-7\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2019-10-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1080/21556660.2019.1684927\",\"citationCount\":\"5\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Drug Assessment\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/21556660.2019.1684927\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2020/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Drug Assessment","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/21556660.2019.1684927","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 5

摘要

目的:探讨肺气肿性胰腺炎(EP)患者生存与死亡特征的差异。方法:通过PubMed检索收集1959年3月至2019年2月的EP病例。42篇文章58例EP符合纳入标准。老年人被定义为年龄大于65岁的个体。收集患者的人口统计学、临床症状、实验室结果、治疗、结局和死亡率数据,并通过卡方检验和学生t检验进行分析。p值结果:纳入男性47人,女性11人,年龄61.3±15.9(平均±标准差)岁。老年人占43.1% (n = 25)。死亡20例,存活38例,总死亡率34.5%。性别、潜在疾病、病因和实验室结果与死亡率无显著相关性。年龄与死亡率显著相关(p = 0.001)。休克在死亡组(100%)比存活组(21%)更常见(p p = 0.002)。结论:EP患者死亡率高(34.5%)。老年、不发热状态和休克的存在与高死亡率有关。为了提高这一具有侵略性的群体的生存率,进一步的前瞻性调查涉及更大的样本量是必要的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

摘要图片

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Risk factors for mortality in emphysematous pancreatitis.

Objective: To investigate the difference in the characteristics between patients with emphysematous pancreatitis (EP) who survived and those who died. Methods: PubMed search was performed to gather EP cases from March 1959 to February 2019. Forty-two articles with 58 EP cases were identified and met the study's inclusion criteria. The elderly were defined as individuals aged >65 years. Data on patients' demographics, clinical symptoms, laboratory results, treatments, outcomes, and mortality were collected and analyzed by chi-square test and Student's t-test. p-Value <.05 (2-tailed) was set as the significance level. Results: Forty-seven men and eleven women aged 61.3 ± 15.9 (mean ± standard deviation) years were included. The elderly accounted for 43.1% (n = 25) of cases. There were 20 mortality cases, and 38 cases survived, with an overall mortality rate of 34.5%. Sex, underlying diseases, etiologies, and laboratory results were not significantly related to mortality. Older age was significantly related to mortality (p = .001). The shock was more commonly seen in the mortality group (100%) than in the survival group (21%) (p < .001). In contrast, fever was less frequent in the mortality group than in the survival group (25 vs. 71%, p = .002). Conclusions: EP patients have a high mortality rate (34.5%). Older age, afebrile status, and presence of shock are associated with high mortality. To improve the survival of this aggressive group, a further prospective investigation involving a larger sample size is necessary.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Drug Assessment
Journal of Drug Assessment PHARMACOLOGY & PHARMACY-
自引率
0.00%
发文量
0
审稿时长
8 weeks
期刊最新文献
Treatment and comorbidity burden among people living with HIV: a review of systematic literature reviews. Investigation of potential substandard dry powder inhalers on EU and North African markets - evaluation of the delivered and fine particle doses. Real world evidence study on treatment patterns and health resource utilization in patients with HR+/HER2- locally advanced or metastatic breast cancer in Korea. A review of the risks of long-term consequences associated with components of the CHOP chemotherapy regimen. Real-world experience of ocrelizumab in multiple sclerosis in an Arab population.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1